ai
Cambridge firm uses AI to revive failed drugs
A UK company founded in 2021 applies artificial-intelligence models to identify why certain drugs failed clinical trials and to redesign them for renewed testing. The firm has raised US$6.9 million and built a pipeline focused on autoimmune diseases and blood cancers.
NA
news.sky.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A Cambridge-based company applies artificial-intelligence models to determine why certain drugs failed clinical trials and then redesigns the most promising candidates. The company was founded in 2021. In February 2025 it closed a US$6.9-million funding round and has since assembled a pipeline that includes potential treatments for autoimmune diseases and blood cancers.
Background on the approach The firm combines chemistry, biology and data-science techniques to analyze how candidate drugs interact with the body and to address toxicity problems identified in earlier trials. Its chief data-science officer holds an undergraduate degree in chemistry and completed a machine-learning internship at a drug-discovery software firm in 2016.
Recognition and outlook In April 2025 the chief data-science officer was named to Forbes magazine’s “30 under 30” list for European science and health care. The company continues to use the same AI-driven process to evaluate additional drug candidates.
Transparency
How sources framed this
NA
NA
Single source — no framing comparison available.
CorroborationModerate · 1 source
